BioMérieux Publishes Q3 2026 Results Call Transcript

By Public Technologies
  • BioMérieux held its Q3 2026 results call November 3 with CEO Pierre Boulud, CFO Guillaume Bouhours and investor-relations head Aymeric Fichet.
  • Management reaffirmed full-year organic sales growth guidance of 3%-5%, with CEBIT growth expected at 0%-10%.
  • Quarterly organic sales rose 8%; unchanged fourth-quarter respiratory activity versus 2025 would put annual growth at the guidance range’s lower end.
  • BIOFIRE non-respiratory sales grew 25%, or 15% excluding the Cyclospora outbreak benefit; management cautioned against extrapolating the underlying performance.
  • The estimated full-year foreign-exchange headwind narrowed to EUR 35 million from EUR 40 million-EUR 50 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMérieux SA published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.